Antitumor Activity and Mechanism Study of Riluzole and Its Derivatives

Xiang-Long Wu\textsuperscript{a}, Liu Liu\textsuperscript{a}, Qing-Chuan Wang\textsuperscript{a}, Hai-Fang Wang\textsuperscript{b}, Xiang-Rong Zhao\textsuperscript{b}, Xu-Bin Lin\textsuperscript{a}, Wen-Jun Lv\textsuperscript{a}, Yin-Bo Niu\textsuperscript{b}, Ting-Li Lu\textsuperscript{a} and Qi-Bing Mei\textsuperscript{a,c,*}

\textsuperscript{a}Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, China. \textsuperscript{b}Laboratory Center of Shaanxi Province People's Hospital, Xi'an, China. \textsuperscript{c}Department of Pharmacology, The Fourth Military Medical University, Xi'an, China.

*Corresponding authors:
E-mail: wuxianglong@nwpu.edu.cn; qbmei@fmmu.edu.cn

Abstract

To explore novel antitumor agents with high efficiency and low toxicity, riluzole alkyl derivatives (4a-4i) were synthesized. Their anti-proliferative activities against HeLa, HepG2, SP2/0, and MCF-7 cancer cell lines were assessed by the CCK-8 assay and compared with human normal liver (LO2) cells. Most of them showed potent cytotoxic effects against four human tumor cell lines and low toxic to LO2 cells. In particular, 2-(N-ethylamine)-6-trifluoromethoxy-benzothiazole (4a) showed an IC\textsubscript{50} value of 7.76 μmol/L in HeLa cells and was found to be nontoxic to LO2 cells up to 65 μmol/L. Furthermore, flow cytometry indicated that 4a could induce remarkable early apoptosis and G2/M cell cycle arrest in HeLa cells. It also impaired the migration ability of HeLa cells in wound healing assays. Western blot results demonstrated that 4a suppressed Bcl-2 protein expression but increased the level of Bax in HeLa cells, and elevated the Bax/Bcl-2 expression ratio. These new findings suggest that 4a exhibited beneficially anti-cervical cancer effect on HeLa cells by inducing HeLa cell apoptosis.

Keywords: Riluzole; Benzothiazole derivatives; Antitumour activity; Synthesis; Mechanism.

Introduction

Cancer can be defined as a genomic disease that appears as a result of dynamic changes of the DNA of an organism’s cells during its lifetime. Cancer can develop in almost any organ or tissue. There are many kinds of cancer such as cervical cancer, breast cancer, prostate cancer, skin cancer, lung carcinoma, multiple myeloma, and T cell leukemia (1). Liver cancer is one of the common malignancies in many countries and an increasing cause of cancer death. Breast cancer is also a global concern, accounting for nearly a quarter of female cancer (2). According to the American Cancer Society, approximately one in eight women in the U.S. will develop invasive breast cancer at some point in their life (3). This toll will continue to increase as the number of women in age groups at risk for breast cancer increases. Cervical cancer (CC) is the second leading cause of cancer morbidity and mortality for women around the world. It is the term for a malignant, neoplasm arising from cells originating in the cervix uteri (4, 5).

The major treatments of cancer include surgery, radiation therapy, chemotherapy, immunotherapy, and vaccine therapy. The chemotherapy drug of cancer includes cisplatin, cyclophosphamide, sorafenib, ifosfamide, doxorubicin, and so on (6). However, these molecules display serious side effects in patients treated for a long time. Thus, it is
important to develop new medicines and novel approaches to increase the antitumor effects against cancer cells in order to increase the efficacy of cancer treatments. Riluzole (2-amino-6-trifluoromethoxybenzothiazole, Compound 1) has an absolute bioavailability of approximate 60%, which is relatively high, and is also able to cross the blood-brain barrier. Riluzole has been approved and marketed for the treatment of ALS in many countries. In addition, it is also effective in animal models of Parkinson’s disease, Huntington’s disease and retinal ischaemia (7). Riluzole exhibits strong anticonvulsant, neuroprotection and antidepressant effects, as well as sedative properties (8).

Furthermore, increasing evidences have confirmed the anti-nociceptive and anti-allodynic efficacy of riluzole in rat models of spinal cord injury (SCI) and in other pain models (9, 10).

Recently, preclinical studies also have demonstrated anti-tumor effects of riluzole in melanoma (11). Speyer and co-workers reported antitumor properties of riluzole in TNBC, which is an aggressive subtype of breast cancer with a high mortality rate (12). Seol et al. described that the riluzole can lead to a suppression of cell proliferation in liver primary cancer cells and cancer cell lines (13). Riluzole can also inhibit proliferation, induce apoptosis and prevent migration of osteosarcoma cells LM7 and glioblastoma cells U87 (14-16). Moreover, riluzole has been observed to reduce the growth of cancer cells in culture or in xenograft models for breast and prostate cancers.

We always focus on the riluzole and its alkyl derivatives for their lipid solubility and extensive physiological activities. Inspired by the antitumor effects of riluzole, we speculated that the alkyl derivatives of riluzole also have antitumor effects. Therefore, in this paper, antitumor properties of riluzole and its alkyl derivatives were evaluated against four cell lines: HeLa (human cervical cancer cell line), HepG2 (human liver cancer cell line), SP2/0 (mouse myeloma cell line), and MCF-7 (human breast cancer cell line).

**Experimental**

**Characterization techniques**

Melting points were measured on a X-4 micro melting point apparatus. IR spectra were recorded on an Equinox-55 FTIR spectrometer. 1H & 13C spectra were recorded on a BRUKER AVANCE instrument. Elemental analyses for C, H, and N were obtained using a Vario EL-III analyzer. All the reagents and solvents used were of analytical grade and were used as supplied unless otherwise stated. TLC was performed on silica gel coated plates for monitoring the reactions.

**Synthesis of compound 2.**

6-Trifluoromethoxy-2-amino-benzothiazole (46.82 g, 0.20 mol), hydrazinium sulfate (NH₂NH₂• H₂SO₄, 39.04 g, 0.30 mol) and hydrazine hydrate (80% aqueous solution, 160 mL) were added to ethylene glycol (500 mL). The mixture was heated and stirred under nitrogen at 130 °C for 4 h. TLC (CH₂Cl₂ / MeOH = 20:1) was used to confirm the completion of the reaction. After cooling to room temperature, the mixture was poured into the ice-water. A lot of gray solid was precipitated. The precipitate was filtered and washed three times with water. The solid was dried in vacuum to constant weight.

**Synthesis of compound 3.**

Compound 2 (24.90 g, 0.10 mol) was slowly added in portions to a solution of SOCl₂ (240 mL) which was pre-heated at 65 °C. The solution was stirred for 5 h at 60 °C. Thionyl chloride was evaporated, then the residue was dissolved in CH₂Cl₂ and solvent was evaporated again. The crude product was purified by column chromatography on silica gel eluted with petroleum ether (60-90 °C) to give compound 3 (21.42 g, Yield 85%) as a white solid.

**General procedure for the preparation of compounds 4a-4i.**

According to our previous research (17), 2-Chloro-6-trifluoromethoxy-benzothiazole (2.54g, 10 mmol) was dissolved in 10 mL ethylamine aqueous solution. The resultant
mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure. The residue was dissolved in CH$_2$Cl$_2$ and washed three times with water, dried over anhydrous Na$_2$SO$_4$, filtered and the solvent was completely removed. The crude material was purified by column chromatography over silica using dichloromethane as eluent to give compound $4a$ as a white amorphous powder (2.22 g, 84.7%). Compounds $4b-4i$ were also prepared by the same procedure from compound $3$ with $n$-butylamine, diethylamin, cyclohexylamine, pyrrolidine, piperidine, morpholine, and 4-methylpipperidine, respectively.

**Cell cultures**

MCF-7 (breast cancer cell line) was cultured in RPMI-1640 medium. HeLa (human cervical cancer cell line), HepG2 (human liver cancer cell line), SP2/0 (mouse myeloma cell line), and LO2 (human normal liver cell line) were cultured in DMEM medium. Each medium was supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% penicillin/streptomycin solution. The cell lines were kept in the incubator at 37°C in a humidified atmosphere (90% RH) containing 5% CO$_2$. The optimal plating density of cell lines was determined to be $5 \times 10^4$. The cell lines SP2/0 and MCF-7 were obtained from Laboratory Center of Shaanxi Province People’s Hospital.

**In-vitro anti-proliferative activity assays**

All of the synthesized compounds (1-3 and $4a-4i$) were assessed for their cytotoxic activity by Cell Counting Kit-8 (Beyotime, China) using the HeLa, HepG2, SP2/0, MCF-7 and LO2 cell lines. $2 \times 10^5$ cells per well were planted into 96-well plates in 100 μL growth medium and incubated for 24 h. Then, the cells were exposed to each compound in growth medium (DMSO < 0.5%) at five different concentrations (1.23, 3.70, 11.11, 33.33, and 100 μmol/L) for 48 h. The mixture was incubated at 37°C under a humidified 5% CO$_2$ atmosphere. After incubation, 10 μL CCK-8 solution was added to each well and the cells were further incubated for 2 h at 37°C according to the CCK-8 Technical Manual. Then, the OD value for each well was read at wavelength 450 nm to determine the cell viability on a microplate reader (Synergy HT, USA). The IC$_{50}$ (50% cell viability inhibition) values were calculated by means of SPSS, GraphPad prism software. The independent experiment was repeated at least three times. The percentage of growth inhibition was calculated as follows according to reference (18),

\[
\% \text{ of growth inhibition} = \left[ 1 - \frac{\text{absorbance of treated cells}}{\text{absorbance of untreated cells}} \right] \times 100\%
\]

**Measurement of anti-migration activity**

Effects of compound $2$ and $4a$ on the cell migration were evaluated in monolayer of HeLa cells. Once the monolayer was formed, a small scratch was made in the plate using a 10 μL pipette tip (0 h, day 1). The monolayer was once washed with PBS to remove debris or the detached cells from the monolayer. The compound $2$ and $4a$ were treated at 25 μmol/L concentration and observed the plates after 24 h (day 2). Images were taken using an inverted microscope (19). The experiments were performed in triplicate.

The relative scratch healing rate was calculated as follows according to reference (20),

\[
\text{Scratch healing rate} = \left( \frac{\text{scratch width at 0 h} - \text{the remaining scratch width at 24 h}}{\text{scratch width in 0 h}} \right) \times 100\%
\]

**Cell morphological assessment**

The cell morphological assessment was carried out as described by Wang S (21). Morphological changes, such as chromosomal condensation and fragmentation in the nuclei of HeLa, were observed by Hoechst 33258 staining. In brief, HeLa cells were seeded at a concentration of $1 \times 10^6$ cells/well in 6-well plate and treated with compound $4a$ (12.5, 25 and 50 μmol/L) for 24 h. Subsequently, the cells were harvested and washed once with PBS and then fixed with 4% paraformaldehyde in PBS for 10 min. After staining with 10 mg/L Hoechst 33258 for 5 min, the cells were visualized under a fluorescent microscope (Nikon, Japan). Viable cells displayed normal nuclear size and uniform fluorescence, whereas apoptotic cells showed condensed, fractured, or distorted nuclei (22).
Flow cytometric analysis of the cell cycle

Cell cycle assay was performed using the cell cycle and apoptosis analysis kit (Beyotime, China) and following the manufacturer’s instructions. The HeLa cells were treated with the indicated concentrations of compound 4a (12.5, 25 and 50 μmol/L) for 24 h. Next, the cells were harvested and washed twice with PBS. The cells were fixed with cold 70% ethanol for 12 h at 4 °C and were harvested and centrifuged at 1000 g for 5 min. Then, the cell density was adjusted to 1×10⁶ cells/mL with PBS. Finally, the cells were stained with a propidium iodide (PI) solution (50 μg/mL). The number of cells in each phase of the cell cycle was analyzed by flow cytometry (FACSCalibur; BD Bioscience, USA).

Flow cytometric analysis of cell apoptosis

The cell apoptosis analysis was evaluated by using the annexin V-FITC apoptosis detection kit (Beyotime, China). Briefly, the HeLa cells (1×10⁶ cells/well) were seeded into 6-well culture plates and incubated for 24 h. Then the cells were incubated for 24 h with the compound 4a (12.5, 25 and 50 μmol/L). The cells were then rinsed, resuspended in 60 μL binding buffer and incubated for 10 min with 5 μL annexin V-FITC at room temperature, followed by an addition of 120 μL binding buffer and 10 μL PI. The solutions were gently mixed and analyzed with the FACScan flow cytometry. The cells that were not treated were used as the control (23).

Western blot assay

HeLa cells were seeded into 6-well plates at 10⁶ cells per well with different concentrations of compound 4a (12.5, 25 and 50 μmol/L) and incubated at 37 °C for 24 h in the presence of 10% FBS. The controls were treated with vehicle (0.5% DMSO). The cells were lysed into ice-cold cell lysis buffer for 30 min and centrifuged at 13000 g for 15 min at 4 °C. The protein concentrations of the supernatant were determined by a BCA protein Assay Kit. Equal amounts of protein lysates were separated on 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred onto PVDF membranes. The membranes were blocked with 5% non-fat milk in TBST (0.1% Tween 20 in TBS) buffer for 2 h, incubated with primary antibodies at 1:1000 dilutions at 4 °C, and washed by TBST four times. Then, the membrane was immunoblotted with Bax, Bel-2, Caspase-3, Cleaved caspase-3, PI3K, and β-actin primary antibodies at 1:1000 dilutions at 4 °C for 12 h. After secondary incubation in horseradish peroxidase-conjugated secondary antibodies at 1:3000 at room temperature for 2 h, protein bands were visualized on X-ray film (Kodak, Japan) using ECL (Beyotime, China). The immunoblots were detected by densitometric analysis. Equal loading of protein in each lane was confirmed by probing with β-actin antibody (24).

Result and Discussion

In order to obtain new compounds, nine N-alkylated derivatives of riluzole were synthesized according to the synthetic procedure shown in Scheme 1. Riluzole was firstly transformed into (6-trifluoromethoxy-benzothiazol-2-yl)-hydrazine, then it was chlorinated by SOCl₂ to obtain 2-chloro-6-trifluoromethoxy-benzothiazole. This intermediate product was treated with nine alkylamines to give N-alkylated derivatives of riluzole respectively. The structures of compounds were confirmed by means of elemental analysis, IR, ¹H NMR and ¹³C NMR. The purity of each compound was determined by HPLC analysis. The values of purity were from 98.06% to 100%, which could meet the requirements of biological experiments. The data of these compounds were given as follows.

Trifluoromethoxy-benzothiazol-2-yl)-hydrazine (Compound 2)

Gray schistose; mp 205-206 °C; IR (KBr) νmax 3362, 3205, 3124, 2963, 2880, 2361, 1660, 1564, 1464, 1261, 1123 cm⁻¹; ¹H NMR (DMSO-d₆, 500 MHz): δ= 9.22 (1H, s, -NH-), 7.79 (1H, s, Ar-H), 7.35 (1H, d, J = 8.7 Hz, Ar-H), 7.17 (1H, d, J = 8.7 Hz, Ar-H), 7.17 (1H, d, J = 5.12 (2H, s, -NH₂); ESI-MS m/z 248.39[M-H]; C₁₈H₁₅F₃N₅O (calcd. 249.21) Anal. Caled. for C₁₈H₁₅F₃N₅O: C, 38.44; H, 2.34; N, 16.75. Found: C, 38.56; H, 2.43; N, 16.86. Its purity by HPLC was 100%.
Antitumor activity of Riluzole derivatives

Chloro-6-trifluoromethoxy benzothiazole (Compound 3)

White solid; mp 38-39 °C; IR (KBr) \( \nu_{\text{max}} \) 3099, 3078, 2361, 1480, 1452, 1262, 1164, 1016, 865 cm\(^{-1}\); \(^1\)H NMR (CDCl\(_3\), 500 MHz): \( \delta = 7.96 \) (1H, d, \( J = 8.9 \) Hz, Ar-H), 7.66 (1H, s, Ar-H), 7.37 (1H, d, \( J = 8.9 \) Hz, Ar-H); ESI-MS: \( m/z \) 251.91 [M-H]; C\(_8\)H\(_3\)ClF\(_3\)NOS (calcld. 252.96); Anal. Calcd for C\(_8\)H\(_3\)ClF\(_3\)NOS: C, 37.88; H, 1.19; N, 5.52. Found: C, 37.95; H, 1.13; N, 5.59. Its purity by HPLC was 98.06%.

(N-Ethylamine)-6-trifluoromethoxy-benzothiazole (Compound 4a)

White solid; mp 133-134 °C; IR (KBr) \( \nu_{\text{max}} \) 3210, 2987, 2922, 2361, 1622, 1584, 1461, 1250, 1152, 807 cm\(^{-1}\); \(^1\)H NMR (CDCl\(_3\), 500 MHz): \( \delta = 7.48 \) (1H, d, \( J = 8.8 \) Hz, Ar-H), 7.46 (1H, s, Ar-H), 7.16 (1H, d, \( J = 8.8 \) Hz, Ar-H), 5.69 (1H, s, -NH-), 3.47 (2H, q, \( J = 7.2 \) Hz, -CH\(_2\)), 1.34 (3H, t, \( J = 7.2 \) Hz, -CH\(_3\)); \(^{13}\)C NMR (CDCl\(_3\), 125 MHz): \( \delta = 167.95 \) (C, S-C-N), 150.94 (C, Ar-O), 143.57 (C, Ar-N), 130.86 (C, Ar-S), 121.65 (C, -CF\(_3\)), 119.68 (C, Ar-4), 118.87 (C, Ar-5), 114.07 (C, Ar-7), 40.43 (C, N-C-C), 14.83 (C, -CH\(_3\)); Anal. Calcd for C\(_{10}\)H\(_9\)F\(_3\)N\(_2\)OS: C, 45.80; H, 3.46; N, 10.65. Found: C, 45.93; H, 3.40; N, 10.76. Its purity by HPLC was 100%.

(N-Propylamine)-6-trifluoromethoxy-benzothiazole (4b)

White solid; mp 88-89 °C; IR (KBr) \( \nu_{\text{max}} \) 3150, 2978, 2861, 1614, 1556, 1463, 1281, 1214, 1162, 808 cm\(^{-1}\); \(^1\)H NMR (CDCl\(_3\), 500 MHz): \( \delta = 7.47 \) (1H, d, \( J = 8.8 \) Hz, Ar-H), 7.45 (1H, s, Ar-H), 7.16 (1H, d, \( J = 8.8 \) Hz, Ar-H), 5.75 (1H, s, -NH-), 3.39 (2H, t, \( J = 7.1 \) Hz, NH-CH\(_2\)), 1.75-1.69 (2H, m, -CH\(_2\)CH\(_3\)), 1.02 (3H, t, \( J = 7.4 \) Hz, -CH\(_3\)); \(^{13}\)C NMR (CDCl\(_3\), 125 MHz): \( \delta = 168.23 \) (C, S-C-N), 151.90 (C, Ar-O), 143.54 (C, Ar-N), 130.84 (C, Ar-S), 121.65 (C, -CF\(_3\)), 119.68 (C, Ar-4), 118.87 (C, Ar-5), 114.07 (C, Ar-7), 47.44 (C, NH-C-C), 22.79 (C, -CH\(_2\)CH\(_3\)), 11.34 (C, -CH\(_3\)); Anal. Calcd for C\(_{11}\)H\(_{11}\)F\(_3\)N\(_2\)OS: C, 47.82; H, 4.01; N, 10.14. Found: C, 47.69; H, 4.20; N, 10.03. Its purity by HPLC was 100%.

Scheme 1. The synthetic procedure of riluzole derivatives and their structures.
(C, Ar-4), 118.64 (C, Ar-5), 113.76 (C, Ar-7), 45.52 (C, N-C-C), 12.80 (C, -CH3); Anal. Calcd for C12H13F3N2OS: C, 49.65; H, 4.51; N, 9.65. Found: C, 49.54; H, 4.62; N, 9.77. Its purity by HPLC was 98.45%.

(N-cyclohexylamine)-6-trifluoromethoxybenzothiazole (4e)
White solid; mp 96-97 °C; IR (KBr) υ max 3427, 3231, 2983, 2858, 1616, 1548, 1456, 1249, 1220, 1162 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz): δ = 7.46 (1H, d, J = 8.8 Hz, Ar-H), 7.44 (1H, s, Ar-H), 7.15 (1H, d, J = 8.7 Hz, Ar-H), 5.53 (s, 1H, -NH-), 3.56 (1H, t, J = 9.6 Hz, -CH-), 2.14-2.10 (2H, m, -CH₂-), 1.80-1.76 (2H, m, -CH₂-); ¹³C NMR (CDCl₃, 100 MHz): δ = 167.12 (C, S-C-N), 151.26 (C, Ar-O), 143.45 (C, Ar-N), 130.98 (C, Ar-S), 121.94 (C, CF₃), 119.62 (C, Ar-4), 118.85 (C, Ar-5), 113.98 (C, Ar-7), 54.64 (C, N-C-C), 33.20 (C, -CH₂-), 25.42 (C, -CH₂-); Anal. Calcd for C₁₂H₁₃F₃N₂OS: C, 53.15; H, 4.78; N, 8.86. Found: C, 53.33; H, 4.68; N, 8.67. Its purity by HPLC was 99.28%.

(N-pyrrolidine)-6-trifluoromethoxybenzothiazole (4f)
White solid; mp 129-130 °C; IR (KBr) υ max 3418, 2969, 2870, 2361, 1614, 1554, 1365, 1243, 1214, 1184 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz): δ = 7.53 (1H, d, J = 8.8 Hz, Ar-H), 7.46 (1H, s, Ar-H), 7.15 (1H, d, J = 8.8 Hz, Ar-H), 3.58 (4H, t, J = 6.3 Hz, -CH₂-N-CH₂), 2.11-2.06 (4H, m, -CH₂CH₂-); ¹³C NMR (CDCl₃, 100 MHz): δ = 165.79 (C, S-C-N), 152.15 (C, Ar-O), 142.91 (C, Ar-N), 131.35 (C, Ar-S), 121.94 (C, -CF₃), 119.49 (C, Ar-4), 119.56 (C, Ar-5), 113.89 (C, Ar-7), 49.52 (C, N-C-C), 25.61 (C, -CH₂-); Anal. Calcd for C₁₂H₁₁F₃N₂OS: C, 49.99; H, 3.85; N, 9.72. Found: C, 53.33; H, 3.68; N, 8.67. Its purity by HPLC was 99.28%.

(N-morpholine)-6-trifluoromethoxybenzothiazole (4h)
White solid; mp 103-105 °C; IR (KBr) υ max 3447, 2974, 2908, 2866, 1618, 1549, 1380, 1339, 1267, 1112, 1026 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz): δ = 7.52 (1H, d, J = 8.8 Hz, Ar-H), 7.49 (1H, s, Ar-H), 7.17 (1H, d, J = 8.8 Hz, Ar-H), 3.84-3.82 (4H, m, -CH₂O-CH₂), 3.63-3.61 (4H, m, -CH₂-N-CH₂); ¹³C NMR (CDCl₃, 125 MHz): δ = 169.45 (C, S-C-N), 151.22 (C, Ar-O), 143.64 (C, Ar-N), 131.19 (C, Ar-S), 121.65 (C, -CF₃), 119.86 (C, Ar-4), 119.57 (C, Ar-5), 113.98 (C, Ar-7), 66.18 (C, N-C-C), 48.51 (C, -CH₂-); Anal. Calcd for C₁₃H₁₃F₃N₂O₂S: C, 51.65; H, 4.33; N, 9.27. Found: C, 51.49; H, 3.54; N, 9.30. Its purity by HPLC was 100%.

2-(N-piperidine)-6-trifluoromethoxybenzothiazole (4i)
White solid; mp 77-78 °C; IR (KBr) υ max 3419, 2940, 2805, 2727, 1614, 1470, 1358, 1271, 1184, 772 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz): δ = 7.47 (1H, d, J = 8.7 Hz, Ar-H), 7.44 (1H, s, Ar-H), 7.13 (1H, d, J = 8.2 Hz, Ar-H), 4.09 (2H, d, J = 12.7 Hz, N-CH₂), 3.12 (2H, t, J = 12.7 Hz, -CH₂-N), 1.77 (2H, d, J = 12.7 Hz, -CH₂-N), 1.68-1.63 (1H, m, -CH₂-N), 1.36-1.26 (2H, m, -CH₂-N), 1.00 (3H, d, J = 6.5 Hz, -CH₃); ¹³C NMR (CDCl₃, 100 MHz): δ = 169.20 (C, S-C-N), 151.80 (C, Ar-O), 143.18 (C, Ar-N), 131.36 (C, Ar-S), 121.93 (C, -CF₃), 119.60 (C, Ar-4), 118.94 (C, Ar-5), 113.83 (C, Ar-7), 49.07 (C, N-C-C), 33.43 (C, -CH₂-N), 30.79 (C, -CH₂-), 21.71 (C, -CH₃); Anal. Calcd for C₁₄H₁₅F₃N₂OS: C, 53.15; H, 4.78; N, 8.86. Found: C, 53.76; H, 4.60; N, 8.70. Its purity by HPLC was 100%.

We optimized the synthetic condition and processing method of compound 3 based on a reference (25). For example, in the preparation process of compound 2, the precipitate was vacuum filtered and triturated in a mixture of...
Antitumor activity of Riluzole derivatives

Table 1. In-vitro cytotoxic activity of all compounds in HeLa, HepG2, SP2/0, MCF-7 and LO2 cell lines.

| Compounds | Cytotoxicity (IC₅₀, μM) |
|-----------|-------------------------|
|           | HeLa                   | HepG2                  | SP2/0                  | MCF-7                  | LO2                   |
| 1         | 48.38±1.89             | 43.49±1.72             | 30.94±1.83             | 29.14±1.70             | 84.6±4.70             |
| 2         | 10.36±0.77             | 28.54±0.91             | 7.45±0.71              | 10.52±0.66             | 100±5.16              |
| 3         | >100                   | >100                   | >100                   | >100                   | 100±6.07              |
| 4a        | 7.76±0.45              | 33.69±1.04             | 51.15±2.73             | 7.72±0.53              | 65±4.38               |
| 4b        | 30.13±1.28             | 17.97±0.88             | 46.44±3.62             | 12.9±0.69              | 32±3.03               |
| 4c        | 16.71±0.94             | >100                   | 58.96±3.32             | 21.94±0.97             | 25±3.12               |
| 4d        | >100                   | >100                   | 48.46±3.41             | 46.6±2.77              | 227±7.82              |
| 4e        | 20.94±0.98             | 20.21±0.93             | 17.73±0.81             | 20.49±1.09             | 33.8±2.40             |
| 4f        | >100                   | >100                   | >100                   | >100                   | 65±3.53               |
| 4g        | >100                   | >100                   | 32.58±1.44             | 25.8±1.21              | 134±5.18              |
| 4h        | >100                   | >100                   | 98.74±3.28             | >100                   | 137±5.28              |
| 4i        | >100                   | >100                   | 11.52±0.85             | >100                   | 112±5.62              |
| Sorafenib | 5.16±0.62              | 12.04±2.12             | 4.25±0.75              | 7.66±0.73              | 11.91±0.32            |

Note: IC₅₀ is the compound concentration required to inhibit cell growth by 50%. Sorafenib was used as a positive control and reference drug (27).

3, 4f, and 4h were negligible because their IC₅₀ values were more than 100 μmol/L, which were above the highest clinically attainable concentration. The structure activity relationship (SAR) couldn’t be concluded, because different activities for these compounds were shown for different cancer cells. For these four cancer cell lines, the highest activity compound for each one was found, such as 4a vs HeLa and MCF-7, 4b vs HepG2, compound 2 vs SP2/0.

The relationship between growth inhibition and concentration of some compounds (1, 2, 4a-4c) were investigated. Results depicted in Figure 1. indicated that these five compounds reduced HeLa cell proliferation in a dose-dependent manner. As we can see from the Figure 1, the percentage of growth inhibition was very close to the reference drug Sorafenib. Compound 4b obviously reduced HepG2 cell proliferation and IC₅₀ value was found to be 17.97 μmol/L. Compound 4b was the best one among all compounds for HepG2 cell. In the SP2/0 cancer cells, the highest activity was observed for compound 2 (IC₅₀ = 7.45 μmol/L). Interestingly, compound 2 with hydrazine substituent had good activity (IC₅₀ in the range of 7.45–28.58 μmol/L) in all the examined cancer cell lines whereas compound 4i with N-4-methyl-1-piperidinyl substituent was found potent (IC₅₀ = 11.52 μmol/L) only in MCF-7 cancer cell line. Riluzole had some activities in all the examined cancer cell lines; however, the IC₅₀ values (the range of 29.14 – 48.38 μmol/L) were higher than some derivatives.

Anti-proliferative activities of compounds
of 4a increased rapidly as the concentration increase. However, other compounds especially riluzole increased slowly. These results also suggested that compound 4a had conspicuously anti-proliferative activity.

The cytotoxic effects were also researched in the normal human liver (LO2) cells to assess the toxicity of these compounds (Table 2). The selectivity index (SI) was calculated as the ratio of the IC₅₀ for the normal cell line (LO2) to the IC₅₀ for a respective cancerous cell line. Higher values of SI indicate greater anticancer specificity and the compounds displaying SI values higher than 3 were considered to be highly selective (28). Some of riluzole derivatives not only had high cytotoxic activity against cancer cells but also displayed low toxicity against normal human liver (LO2) cells and their SI values were higher than 3.5. The SI values of compound 4a in HeLa and MCF-7 cancer cells were 8.37 and 8.41, respectively. The SI value of compound 2 in SP2/0 cancer cells was as high as 13.42, which had shown greater anticancer specificity. In this paper, compound 4a was investigated in further research for its excellent anticancer activity.

Cancer cell migration and invasion is the main feature responsible for malignant tumor progression and metastasis (29). Cellular migration, the major process in cancer metastasis starts with the loss of cell-cell adhesion (helps in the detachment of cells from primary tumor) followed by loss of cell-matrix interaction (drives the cells to invade to the surrounding stroma) (30). To investigate the effect of compound 2 and 4a on the cell migration ability, we performed the vitro scratch wound healing assay by using HeLa cancer cells. As shown in Figure 2, the wound gap of control group (vehicle) almost closed after 24 h without treatment. However, the gap width of 4a group didn’t change after treatment with compound 4a for 24 h. HeLa

![Figure 1. The relationship between growth inhibition and concentration of compounds 1, 2, 4a-4c on HeLa cells.](image)

| Compounds | SI  |
|-----------|-----|
|           | HeLa | HepG2 | SP2/0 | MCF-7 |
| 1         | 1.75 | 1.95  | 2.73  | 2.90  |
| 2         | 9.65 | 3.50  | 13.42 | 9.51  |
| 4a        | 8.37 | 1.93  | 1.27  | 8.41  |
| 4b        | 1.07 | 1.79  | 0.69  | 2.50  |
| 4c        | 1.53 | 0.26  | 0.43  | 1.17  |
| 4e        | 1.62 | 1.67  | 1.91  | 1.65  |
| 4g        | 1.34 | 1.34  | 4.12  | 5.20  |
| 4i        | 1.12 | 1.12  | 9.68  | 1.12  |

Note: The selectivity index (SI) was calculated for each compound using the formula: SI = IC₅₀ for normal cell line LO2/IC₅₀ for respective cancerous cell line. A beneficial SI > 1.0 indicates a compound with efficacy against tumor cells greater than the toxicity against normal cells.
Cell migration was significantly slower in the 4a group than in the control group.

As shown in Figure 3, the relative scratch healing rate of compound 4a was less than 20%, the scratch healing rate of compound 2 was less than 40%, and the wound healing rate of blank group was as high as 70%. So compound 4a had significant anti-migration effect which indicates that it has the potential to inhibit HeLa cell metastasis \textit{in-vivo}. The data from the scratch assay demonstrated that compound 2 could also prevented migration of HeLa cells.

The concentration was an important factor. If the concentration was too high, the toxicity was so strong that the monolayer of cell will disappear. However, the effect on the migration can’t be observed in low concentration. Three drug concentrations (12.5, 25 and 50 μmol/L) were chosen in our experiment and the 25 μmol/L was the best one.

The changes of morphological features, such as cell shrinkage, chromatin condensation, and nuclear membrane blebbing were the characteristics of apoptotic cells (31). The morphological assay of cell death was investigated by Hoechst 33258 staining. Hoechst 33258, which stains the cell nuclei and emits fluorescence allowing the visualization of nuclear morphological changes, was a membrane permeable dye. We had observed the morphological changes associated with the cells upon the treatment with compound 4a using fluorescence microscopy. The results were given in Figure 4. The results showed that the control cells were normal and the nuclei were round and homogeneous. However, the nuclei treated with compound 4a for 24 h exhibited nuclear condensation and fragmentation which is the typical characteristics of apoptosis. This phenomenon was observed in a dose-dependent manner as we can see from the Figure 4.

To further investigate the mechanism of

![Figure 2](image-url)

\textbf{Figure 2.} Effects of compounds 2 and 4a on cell migration by wound healing assay (25μmol/L). Upper panel: Vehicle, 4a and 2 groups at 0-h time point. Bottom panel: Vehicle, 4a and 2 groups at 24-h time point.

![Figure 3](image-url)

\textbf{Figure 3.} Anti-migration scratch healing rate of compounds 2, 4a on HeLa cells (N = 3, ***p < 0.01).
compound 4a on HeLa, we examined the effect of 4a on cell cycle distribution by flow cytometry. As shown in Figure 5, the cells in the G2/M phase increased from 3.66% in control group to 3.85%, 6.63%, and 8.00% in a concentration-dependent manner in HeLa cell lines. These results revealed that compound 4a dose-dependently arrested the cell cycle at the inhibitory effect of 4a was associated with cell apoptosis, we performed annexin V-FITC/PI double-staining and flow cytometry of HeLa cells. The early apoptotic rates were 4.76 %, 9.63 %, and 19.81% at 4a concentrations of 12.5, 25 and 50 μmol/L, respectively (Figure 6). Compound 4a could induce remarkable early apoptosis of HeLa in a dose-dependent manner (Figure 7). These results suggested that the inhibition of cell growth was caused by the induction of early apoptosis.

The Bcl-2 family proteins can either positively or negatively regulate apoptosis. The pro-apoptotic family members include Bax, Bad and Bok, while the anti-apoptotic members of this family include Bel-2, Bel-XL, and Bcl-w (32, 33). We examined the effects of 4a on the expression of Bax, Bel-2, Caspase-3, Cleaved caspase-3, and PI3K by western blot analysis (Figure 8). As shown in Figure 9, western blot results demonstrated that 4a reduced the expression of Bel-2, but increased the levels of Bax and Cleaved caspase-3 in HeLa cells. There were not remarkably concentration-dependent change in the expression levels of PI3K and Caspase-3 in HeLa cells. As we can see from Figure 8

Figure 4. Hoechst 33258 staining of compound 4a in HeLa cell line. (A) Control; (B) 12.5 μmol/L 4a for 24 h; (C) 25 μmol/L 4a for 24 h; (D) 50 μmol/L 4a for 24 h.

Figure 5. Effect of compound 4a on cell cycle. The distribution of HeLa cells in the three phases of the cell cycle following treatment with compound 4a is depicted in representative plots.

Figure 5. Effect of compound 4a on cell cycle. The distribution of HeLa cells in the three phases of the cell cycle following treatment with compound 4a is depicted in representative plots.
Antitumor activity of Riluzole derivatives

Figure 6. Flow cytometric analysis of HeLa cells treated with compound 4a. The percentages of apoptotic cells are shown in representative plots. (a) Control (b) 12.5 μmol/L (c) 25 μmol/L (d) 50 μmol/L.

Figure 7. Effect of compound 4a on the early apoptotic rates (μM = μmol/L).

Figure 8. The effects of compound 4a on the protein levels were assessed by Western blot.

and Figure 9, Cleaved caspase-3 which is an apoptotic marker was clearly increased in the HeLa cells.

The release of cytochrome c from mitochondria to cytosol is one of the early events prior to apoptosis. And it is widely accepted that the release of cytochrome c into cytosol is tightly regulated by the ratio between the Bcl-2 family proteins, especially the anti-apoptotic protein (Bcl-2) and pro-apoptotic protein (Bax) protein, all of which have been demonstrated to be responsible for the regulation of the apoptotic process (34). As we can see from Figure 9, compound 4a could inhibit Bcl-2 and induce Bax expression. Furthermore, the increase of the Bax/Bcl-2
expression ratio was enhanced (Figure 10), which enhanced the membrane permeability of mitochondria and thereby 4a promoted cell apoptosis. These results suggested that 4a promotes apoptosis in HeLa cells by reducing the expression of anti-apoptotic proteins and increasing the expression of pro-apoptotic proteins.

**Conclusion**

In summary, riluzole alkyl derivatives had been synthesized firstly and their anti-proliferative activities against HeLa, HepG2, SP2/0 and MCF-7 cancer cell lines were assessed. Most of them show forceful cytotoxic effects against the four cancer cell lines and low toxic to normal liver cells. In particular, 2-(N-ethyl-amine)-6-trifluoromethoxy-benzothiazole (4a) showed a very low IC₅₀ value in HeLa cells and admirable anticancer specificity. Furthermore, flow cytometry indicated that 4a could induce remarkable early apoptosis and G2/M cell cycle arrest in HeLa cells. Wound healing assays indicated that the 4a show an excellent anti-migration activity. Western blot results demonstrated that 4a promotes apoptosis in HeLa cells by elevating the Bax/Bcl-2 expression ratio. These new findings suggest that 4a exhibited beneficially anti-cervical cancer effect on HeLa cells by inducing HeLa cell apoptosis.

**Acknowledgments**

The work was supported by the National Natural Science Foundation of China (No. 21202130), the Fundamental Research Funds for the Central Universities (No. 3102014JCQ15005), the Natural Science Foundation Research Project of Shaanxi Province (No. 2015JM2067), the Seed Foundation of Innovation and Creation for Graduate Students in Northwestern Polytechnical University (No. Z2017239), and the national innovation experiment program for university students (No. 201710699335).

**References**

(1) Ozcan AG. Cytoprotective effects of amifostine
and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index. Cancer Chemother. Pharmacol. (2005) 56: 221–9.

(2) Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics. CA Cancer J. Clin. (2015) 65: 87–108.

(3) Siegel RL, Miller KD and Jemal A. Cancer statistics. CA Cancer J. Clin. (2016) 66: 7–30.

(4) Zagouri F, Sergentanis TN, Chrysikos D, Filipits M and Bartsch R. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol. Oncol. (2012) 126: 291–298.

(5) Yueran Li, Xiao S, Dan L and Xue M. P16INK4A is required for cisplatin resistance in cervical carcinoma SiHa cells. Oncol. Lett. (2015) 9: 1104–1108.

(6) Peraltazaragoza O, Pérezplesencia C, Salazarléon J, Gómezcórcon C and Madridmarina V. Targeted treatments for cervical cancer: a review. Oncol. Targets Ther. (2012) 5: 315–328.

(7) Jehle T, Bauer J, Blauth E, Hummel A, Darstein M and Freiman TM. Effects of riluzole on electrically evoked neurotransmitter release. Br. J. Pharmacol. (2000) 130: 1227–34.

(8) Cheah BC, Yucic S, Krishnan AV and Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. (2010) 17: 1942–59.

(9) Kitzman PH. Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat. Neurosci. Lett. (2009) 455: 150–153.

(10) Munro G, Erichsen HK and Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology (2007) 53:609–618.

(11) Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA and Goydos JS. The glutamate release inhibitor riluzole decreases migration, invasion, and proliferation of melanoma cells. J. Invest. Dermatol. (2010) 130: 2240–9.

(12) Speyer CL, Nasser MA, Hachem AH, Bukhsh MA, Jafry WS and Kanssa RM. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. Breast Cancer Res. Treat. (2016) 157: 217–228.

(13) Seol HS, Lee SE, Song JS, Lee HY, Park S and Kim I. Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production. Cancer Lett. (2016) 382: 157–65.

(14) Yelskaya Z, Carrillo V, Dubisz E, Kulzar H, Morgan D and Mahajan SS. Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa. PLoS One (2013) 8:e64588.
bergenin/cinnamic acid hybrids. *Eur. J. Med. Chem.* (2017) 133: 319–28.

(25) Mignani S, Audiau F and Blevec JL. Versatile methods for the synthesis of 2-amino-6-trifluoromethoxy-(nitro) benzothiazoles. *Synth. Commun.* (1992) 22: 2769–780.

(26) Saha P, Ramana T, Purkait N, Ali MA and Paul R. Ligand-free copper-catalyzed synthesis of substituted benzimidazoles, 2-aminobenzimidazoles, 2-aminobenzothiazoles, and benzoxazoles. *J. Org. Chem.* (2009) 74: 8719–25.

(27) Yao GD, Sun Q, Song XY, Huang XX, and Song SJ. Flavan enantiomers from Daphne geraldii selectively induce apoptotic cell death in p53-null hepatocarcinoma cells *in-vitro*. *Chem. Biol. Interact.* (2018) 289: 1–8.

(28) Machana S, Weerapreeyakul N, Barusrux S, Nonpunya A, Sripunidkulchai B and Thitimetharoch T. Cytotoxic and apoptotic effects of six herbal plants against the human hepatocarcinoma (HePG2) cell line. *Chin. Med.* (2011) 6: 39–46.

(29) Kamath PR, Sunil D, Joseph MM, Abdul A.A and Sreerlekh TT. Indole-coumarin-thiadiazole hybrids: An appraisal of their MCF-7 cell growth inhibition, apoptotic, antimitastatic and computational Bel-2 binding potential. *Eur. J. Med. Chem.* (2017) 136: 442–1.

(30) Yin TQ, Yang XO, Jiao FY, Huang LP, Tang XD and Ren BQ. Pseudomonas aeruginosa mannose-sensitive hemagglutinin inhibits proliferation and invasion via the PTEN/AKT pathway in HeLa cells. *Oncotarget* (2016) 7: 37121–31.

(31) Tong H, Jia L, Xue J, Li H, Xu F, Cheng K, Li D, Li Z, Gao M and Hua H. Scutellarin derivatives as apoptosis inducers: Design, synthesis and biological evaluation. *Eur. J. Med. Chem.* (2017) 135: 270–81.

(32) Cory S and Adams JM. Killing cancer cells by flipping the Bel-2/Bax switch. *Cancer Cell.* (2005) 8: 5–6.

(33) Adams JM and Cory S. The Bel-2 apoptotic switch in cancer development and therapy. *Oncogene* (2007) 26: 1324–37.

(34) Harris MH and Thompson CB. The role of the Bel-2 family in the regulation of outer mitochondrial membrane permeability. *Cell Death Differ.* (2000) 7: 1182–91.

This article is available online at http://www.ijpr.ir